Correlation between digestion of the lipid phase of smedds and release of the anti-HIV drug UC 781 and the anti-mycotic drug enilconazole from smedds

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 66, Issue 2, 2007, Pages 173-181

  Goddeeris, C ^a   Coacci, J ^a   Van den Mooter, G ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Drug release; Fatty acid liberation; Oil digestion; Smedds

Indexed keywords

ALCOHOL; CAPTEX 200P; CREMOPHOR; EMULSIFYING AGENT; ENILCONAZOLE; FATTY ACID; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; PHOSPHOLIPID; POLYSORBATE 80; SIMULSOL 1292; UNCLASSIFIED DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FATTY ACID TRANSPORT;

ANILIDES; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; EMULSIONS; ETHANOL; FATTY ACIDS; FURANS; HYDROLYSIS; IMIDAZOLES; LIPASE; OILS; PARTICLE SIZE; SOLUBILITY; SOLVENTS; SURFACE-ACTIVE AGENTS; TIME FACTORS;

EID: 34247489694     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.10.005     Document Type: Article

References (33)

1. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Humberstone A.J., and Charman W.N. Lipid-based vehicles for the oral delivery of poorly water soluble drug. Adv. Drug Del. Rev. 25 (1997) 103-128
3. Uede C.T., Lemaire M., Gsell G., Misslin P., and Nussbaumer K. Apparent dose-dependent oral absorption of cyclosporine A in rats. Biopharm. Drug Dispos. 5 (1984) 141-151
4. Grevel J., Nuesch E., Abisch E., and Kutz K. Pharmacokinetics of oral cyclosporine A (Sandimmun) in healthy subjects. Eur. J. Clin. Pharmacol. 31 (1986) 211-216
5. Vanderscher J., and Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant. Proc. 26 (1994) 2925-2927
6. Hernell O., Staggers J.E., and Carey M.C. Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase behaviour and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 29 (1990) 2041-2056
7. Porter C.J.H., and Charman W.N. In vitro assessment of oral lipid based formulations. Adv. Drug Delivery Rev. 50 (2001) S127-S147
8. Vetter R.D., Carey M.C., and Patton J.S. Coassimilation of dietary fat and benzopyrene in the small intestine: an absorption model using killifish. J. Lipid Res. 26 (1985) 428-434
9. Kang B.K., Lee J.S., Chon S.K., Jeong S.Y., Yuk S.H., Khang G., Lee H.B., and Cho S.H. Development of self-micro-emulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pham. 274 (2004) 65-73
10. Pouton C.W. Effects of the inclusion of a model drug on the performance of self-emulsifying formulations. J. Pharm. Pharmacol. 36 (1985) 51P
11. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 11 (2000) S93-S98
12. Charman S.A., Charman W.N., Rogge M.C., Wilson T.D., Dutko F.J., and Pouton C.W. Self-emulsifying systems: formulation and biological evaluation of an investigative lipophilic compound. Pharm. Res. 9 (1992) 87-94
13. Constantinides P. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12 (1995) 1561-1572
14. Greiner R.W., and Evans D.F. Spontaneous formation of a water-continuous emulsion from water-in-oil microemulsion. Langmuir 6 (1990) 1793-1796
15. Shah N.H., Carvajal M.T., Patel C.I., Infeld M.H., and Melick A.W. Self-emulsifying drug delivery systems with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 106 (1994) 15-23
16. Gershanik T., and Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50 (2000) 179-188
17. Balzarini J., Brouwer W.G., Dao D.c., Osika E.M., and De Clercq E. Identification of novel thiocarboxanilide derivatives that supress a variety of drug-resistant mutant human deficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40 (1996) 1454-1466
18. Balzarini J., and De Clercq E. The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with other antiretroviral drugs. Antiviral Chem. Chemother. 8 (1996) 197-204
19. Hnilica K., and Medleau L. Evaluation of topically applied enilconazole for the treatment of dermatophytosis in a Persian cattery. Vet. Derm. 13 (2002) 23-28
20. Moriello K., Deboer D., Volk L., Sparkes A., and Robinson A. Development of an in vitro, isolated, infected sore testing model for disinfectant testing of Microsporum canis isolates. Vet. Derm. 15 (2004) 175-180
21. MacGregor K.J., Embleton J.K., Lacy J.E., Perry A., Solomon L.J., Seager H., and Pouton C.W. Influence of lipolysis on drug absorption from gastro-intestinal tract. Adv. Drug Delivery Rev. 25 (1997) 33-46
22. Sek L., Porter C.J.H., and Charman W.N. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J. Pharm. Biomed. Anal. 25 (2001) 651-661
23. Sek L., Porter C.J.H., Kaukonen A.M., and Charman W.N. Evaluation of the in-vitro digestion profiles of long and medium chain triglycerides and the phase behaviour of their lipolytic products. J. Pharm. Pharmacol. 59 (2002) 29-41
24. Kaukonen A.M., Boyd B.J., Porter C.J.H., and Charman W.N. Drug solubilization behaviour during in vitro digestion of simple triglyceride lipid solution formulations. Pharm. Res. 21 (2004) 245-253
25. Larsson A., and Erlanson-Albertsson C. Effect of phophatidylcholine and free fatty acids on the activity of pancreatic lipase-colipase. Biochim. Biophys. Acta 876 (1986) 543-550
26. Embleton J.K., and Pouton C.W. Structure and function of gastro-intestinal lipases. Adv. Drug Delivery Rev. 25 (1997) 15-32
27. Dahim M., and Brockman H. How colipase-fatty acid interactions mediate adsorption of pancreatic lipase to interfaces. Biochemistry 37 (1998) 8369-8377
28. Brockman H.L. Kinetic behavior of the pancreatic lipase-colipase-lipid system. Biochimie 82 (2000) 987-995
29. Sugar I.P., Mizuno N.K., Momsen M.M., and Brockman H.L. Lipid lateral organization in fluid interfaces controls the rate of colipase association. Biophys. J. 81 (2001) 3387-3397
30. Patton J.S., and Carey M.C. Watching fat digestion. Science 204 (1979) 145-148
31. Hermoso J., Pignol D., Kerfelec B., Crenon I., Chapus C., and Fontecillacamps J.C. Lipase activation by non-ionic detergents - the crystal structure of the porcine lipase-colipase-tetraethylene glycol monooctyl ether complex. J. Biol. Chem. 271 (1996) 18007-18016
32. Solomon L.J., Embleton J.K., and Pouton C.W. Inhibition of lipolysis of medium-chain triglycerides by non-ionic surfactants, a structure/activity study. In: Couvreur P., Duchene D., and Kallas I. (Eds). Formulation of poorly available drugs for oral administration (1996), Editions de Santé, Paris 437-438
33. Staggers J.E., Hernell O., Stafford R.J., and Carey M.C. Physical-chemical behaviour of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behaviour and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry 29 (1990) 2028-2040